Table 1 Characteristics of studies included in systematic review
Author Year | Publication type | Exposure | Comparator | Number | Age | Follow-up | Funding |
|---|---|---|---|---|---|---|---|
Leder 2015 | Multicenter II-RCT (NCT00542425) | Abaloparatide: 20 µg (n = 43); 40 µg (n = 43); 80 µg (n = 45); | Placebo (n = 45); Teriparatide 20 μg (n = 45) | 222 | 20 µg: 66.3 ± 7.0; 40 µg: 64.5 ± 7.4; 80 µg: 64.8 ± 7.2; Placebo: 65.0 ± 7.1; Teriparatide: 64.5 ± 7.5 | 48 weeks1 | Radius Health Inc |
Miller 2016 | Multicenter III-RCT (NCT01343004) | Abaloparatide: 80 µg (n = 824) | Placebo (n = 821); Teriparatide 20 μg (n = 818) | 2463 | 80 µg: 68.9 ± 6.5; Placebo: 68.7 ± 6.5; Teriparatide: 68.8 ± 6.6 | 72 + 4 weeks2 | Radius Health Inc |
Miller 2021* | Multicenter I-RCT (NCT04366726) | Abaloparatide*: 300 μg (n = 22) | / | 22 | 300 μg: 65.2 ± 6.4 | 4 + 1 weeks3 | Radius Health Inc |
NCT01674621 | Multicenter II-RCT (NCT01674621) | Abaloparatide#: 50 µg (n = 47); 80 µg (n = 49); 100 µg (n = 46); 150 µg (n = 43); | Placebo (n = 46) | 231 | 50 µg: 65.9 ± 4.83; 80 µg: 66.4 ± 5.48; 100 µg: 65.7 ± 5.26; 150 µg: 66.3 ± 6.46; Placebo: 66.5 ± 7.27 | 24 + 4 weeks4 | Radius Health Inc |
Eastell 2019 | Post hoc analysis5 | Abaloparatide: 80 µg (n = 824) | Teriparatide 20 μg (n = 818) | 1642 | 80 µg: 68.9 ± 6.5; Teriparatide: 68.8 ± 6.6 | – | Radius Health Inc |
McCloskey 2019 | Post hoc analysis | Abaloparatide (n = 459) | Placebo (n = 468); Teriparatide (n = 473) | 1400 | Abaloparatide: 69.9 ± 6.67; Placebo: 70.0 ± 6.27; Teriparatide: 69.9 ± 6.37 | – | Radius Health Inc |
Reginster 2018 | Post hoc analysis | Abaloparatide: 80 µg (n = 824) | Placebo (n = 821); Teriparatide 20 μg (n = 818) | 2463 | 80 µg: 68.9 ± 6.5; Placebo: 68.7 ± 6.5; Teriparatide: 68.8 ± 6.6 | – | Radius Health Inc |
Leder 2019 | Post hoc analysis | Abaloparatide 80 µg/Alendronate (n = 558) | Placebo/Alendronate (n = 581) | 1139 | 80 µg: 68.9 ± 6.5; Placebo: 70.1 ± 6.3 | – | Radius Health Inc |
Reginster 2017 | Post hoc analysis | Abaloparatide: 80 µg (n = 824) | Placebo (n = 821) | 1645 | 80 µg: 68.9 ± 6.5; Placebo: 68.7 ± 6.5 | – | Radius Health Inc |
Bone 2018 | Post hoc analysis | Abaloparatide 80 µg/Alendronate (n = 558) | Placebo/Alendronate (n = 581) | 1139 | 80 µg: 68.9 ± 6.5; Placebo: 70.1 ± 6.3 | – | Radius Health Inc |
Cosman 2017 | Post hoc analysis | Abaloparatide 80 µg/Alendronate (n = 558) | Placebo/Alendronate (n = 581) | 1139 | 80 µg: 68.9 ± 6.5; Placebo: 70.1 ± 6.3 | – | Radius Health Inc |
Watts 2019 | Post hoc analysis | Abaloparatide: 80 µg (n = 824) | Placebo (n = 821); Teriparatide 20 μg (n = 818) | 2463 | 80 µg: 68.9 ± 6.5; Placebo: 68.7 ± 6.5; Teriparatide: 68.8 ± 6.6 | – | Radius Health Inc |
McCloskey 2017 | Post hoc analysis | Abaloparatide: 80 µg (n = 824) | Placebo (n = 821) | 1645 | 80 µg: 68.9 ± 6.5; Placebo: 68.7 ± 6.5 | – | Radius Health Inc |
Cosman 2016 | Post hoc analysis | Abaloparatide: 80 µg (n = 824) | Placebo (n = 821) | 1645 | 80 µg: 68.9 ± 6.5; Placebo: 68.7 ± 6.5 | – | Radius Health Inc |
Saag 2020 | Post hoc analysis | Abaloparatide (n = 94) | Placebo (n = 103); Teriparatide (n = 99) | 296 | Abaloparatide: 59.4 ± 3.6; Placebo: 59.9 ± 3.3; Teriparatide: 58.8 ± 3.8 | – | Radius Health Inc |
McClung 2018 | Post hoc analysis | Abaloparatide: 80 µg (n = 824) | Placebo (n = 821) | 1645 | 80 µg: 68.9 ± 6.5; Placebo: 68.7 ± 6.5 | – | Radius Health Inc |